Gambogic acid inhibits the catalytic activity of human topoisomerase IIα by binding to its ATPase domain

被引:98
作者
Qin, Yuxin
Meng, Linghua
Hu, Chaoxin
Duan, Wenhu
Zuo, Zhili
Lin, Liping
Zhang, Xiongwen
Ding, Jian
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Div Antitumor Pharmacol, Shanghai 201203, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Div Phytochem, Shanghai, Peoples R China
[3] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Drug Discovery & Design Ctr, Shanghai, Peoples R China
关键词
D O I
10.1158/1535-7163.MCT-07-0147
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study is intended to characterize the cellular target of gambogic acid (GA), a natural product isolated from the gamboge resin of Garcinia hurburyi tree, which possesses potent in vitro and in vivo antitumor activities. The antiproliferative activity of GA was further confirmed here in a panel of human tumor cells and multidrug-resistant cells. We found that GA significantly inhibited the catalytic activity of topoisomerase (Topo) II and, to a comparatively less extent, of Topo I, without trapping and stabilizing covalent topoisomerase-DNA cleavage complexes. Down-regulation of Topo II alpha but not Topo I and Topo II beta, reduced GA-induced apoptosis and the phosphorylation of c-Jun, and restored cell proliferation upon GA treatment. Moreover, GA antagonized etoposide-induced DNA damage and abrogated the antiproliferative activity of etoposide, whereas it did not affect camptothecin-induced DNA damage. By dissecting the actions of GA on the individual steps of Topo II alpha catalytic cycle, we found that GA inhibited DNA cleavage and ATP hydrolysis. Moreover, GA directly bound to the ATPase domain of II alpha, and may share common binding sites with ATP. The results reported here show that GA exerts its antiproliferative effect by inhibiting the catalytic activity Topo II alpha. They also indicate that GA inhibits Topo II alpha-mediated DNA cleavage and modulate the activity of Topo II poisons, which provide rationale for further clinical evaluation of GA.
引用
收藏
页码:2429 / 2440
页数:12
相关论文
共 44 条
[1]   Catalytic inhibitors of DNA topoisomerase II [J].
Andoh, T ;
Ishida, R .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :155-171
[2]   Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity [J].
Binaschi, M ;
Capranico, G ;
DalBo, L ;
Zunino, F .
MOLECULAR PHARMACOLOGY, 1997, 51 (06) :1053-1059
[3]   Intercalators as anticancer drugs [J].
Braña, MF ;
Cacho, M ;
Gradillas, A ;
de Pascual-Teresa, B ;
Ramos, A .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (17) :1745-1780
[4]  
Capranico G, 1999, Cancer Chemother Biol Response Modif, V18, P125
[5]  
Cornarotti M, 1996, MOL PHARMACOL, V50, P1463
[6]   Dual topoisomerase I/II inhibitors in cancer therapy [J].
Denny, WA ;
Baguley, BC .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (03) :339-353
[7]   Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice [J].
Fortune, JM ;
Osheroff, N .
PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, VOL 64, 2000, 64 :221-253
[8]   Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage [J].
Fortune, JM ;
Osheroff, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (28) :17643-17650
[9]   THE 24 KDA N-TERMINAL SUBDOMAIN OF THE DNA GYRASE-B PROTEIN BINDS COUMARIN DRUGS [J].
GILBERT, EJ ;
MAXWELL, A .
MOLECULAR MICROBIOLOGY, 1994, 12 (03) :365-373
[10]   Topoisomerase Enzymes as Therapeutic Targets for Cancer Chemotherapy [J].
Giles, Gregory I. ;
Sharma, Ram P. .
MEDICINAL CHEMISTRY, 2005, 1 (04) :383-394